M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

Bell Financial Group (ASX:BFG) has delivered a strong full-year result, underscoring the benefits of its evolution from a traditional stockbroking house into a more diversified wealth management business. The Group’s newly structured Markets and Platforms divisions highlight this transition, with Platforms emerging as a key earnings engine supported by recurring revenue and scalable technology. Co-Chief Executive Officer Arnie Selvarajah joins The Stock Network’s Lel Smits to discuss how Bell’s transformation strategy is reshaping the business, what’s driving momentum across its divisions, and where future growth opportunities may lie for retail investors. 1. Transformation strategy Bell Financial Group has repositioned itself as a more diversified wealth manager rather than just a broking business. What are the benefits you have seen already come in your results, arising from this strategy? 2. Platforms as a growth engine The Platforms division is now contributing a significant share of group earnings. What makes this segment particularly attractive from a long-term shareholder perspective, and how scalable is the model from here? 3. Capital management and growth priorities With a strong balance sheet and consistent dividend profile, how is Bell Financial Group balancing reinvestment for growth with shareholder returns in the year ahead? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Bell Financial Group (ASX:BFG): Diversified wealth strategy gains traction as platforms drive growth
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4yMkNBN0M4QUJEQzYxMjA3

Bell Financial Group (ASX:BFG): Diversified wealth strategy gains traction as platforms drive growth

Far East Gold (ASX:FEG) is advancing a quality portfolio of six copper and gold projects across Indonesia and Australia, underpinned by combined JORC resources of 1.54Moz gold and 190Mlb copper. During the quarter, the Company delivered high-grade drilling results at the Idenburg Project in Papua, expanded mineralised zones at Sua and North Bermol, progressed permitting milestones, and recommenced drilling at Mount Clark West in Queensland following a wet-season pause. Managing Director and CEO Shane Menere joins The Stock Network’s Lel Smits to discuss the latest drilling success, regulatory progress and how Far East Gold is positioning for sustained discovery-driven growth across its portfolio. 1. High-grade growth at Idenburg – Sua and North Bermol, Indonesia You’ve delivered very high-grade gold hits at Sua, including visible gold, and the system remains open in multiple directions. In simple terms, how big could this get? And with North Bermol also returning strong results, could Idenburg potentially host more than one meaningful gold deposit? 2. Strong newsflow across multiple projects With drilling underway at Sua and North Bermol, plans progressing at Kwaplu, and key permits now secured, how does this set the Company up for steady newsflow and how important is having multiple drill programs running at the same time? 3. Mount Clark West – copper upside in Queensland At Mount Clark West in Queensland, early drilling has identified signs of a potential copper-gold system, and the permit has now been extended to 2031. What would you need to see in upcoming assay results to confirm this could be a large-scale copper discovery and what are your immediate priorities? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Far East Gold (ASX:FEG): High-grade gold growth in Indonesia & emerging copper potential in QLD
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BNjBCMUFCN0Q5QzUyMjlG

Far East Gold (ASX:FEG): High-grade gold growth in Indonesia & emerging copper potential in QLD

Arovella Therapeutics (ASX:ALA) is a biotechnology company developing invariant natural killer T (iNKT) cell therapies for the treatment of blood cancers and solid tumours. In January 2026, Arovella achieved a major regulatory milestone with U.S. FDA acceptance of its investigational new drug (IND) for lead program ALA-101, validating its preclinical data, manufacturing process and clinical development plan and clearing the path for a first-in-human Phase 1 trial. The investigational new drug (IND) acceptance also establishes a regulatory framework for Arovella’s broader CAR-iNKT platform, supporting the advancement of additional programs including ALA-105 for gastric cancer. Ahead of Wholesale Investor’s Emergence 2026 Conference, CEO and Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about the significance of this milestone and what comes next as Arovella enters the clinic. 1. Entering the clinic The FDA has now accepted Arovella’s investigational new drug (IND) for ALA-101, allowing the Company to begin its first-in-human Phase 1 trial. What does this investigational new drug (IND) acceptance mean for Arovella at a company level, and why is it such an important inflection point as you move from preclinical development into the clinic? 2. Building value beyond ALA-101 Alongside ALA-101, Arovella is advancing a broader CAR-iNKT platform, including solid tumour programs such as ALA-105. How does the successful IND for ALA-101 help de-risk and accelerate the development of the wider pipeline, and what should investors be watching over the next 12 months? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Arovella Therapeutics (ASX:ALA): FDA clears IND for next-gen iNKT therapy
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4wOTkzRUNGQkU5QzI1QTA3

Arovella Therapeutics (ASX:ALA): FDA clears IND for next-gen iNKT therapy

Percheron Therapeutics (ASX:PER) is an international biotechnology company developing novel therapies for oncology and rare diseases. During the December 2025 quarter, the Company reported final Phase I data for HMBD-002, confirming strong safety and encouraging efficacy signals, and outlined a modular Phase II clinical trial with manufacturing scheduled for the second quarter of this year. Ahead of Wholesale Investor’s Emergence 2026 Conference, CEO and Managing Director Dr James Garner speaks with The Stock Network’s Lel Smits about clinical progress and the path into Phase II. 1. Phase I results and clinical validation Final Phase I data for HMBD-002 showed strong safety and early signs of efficacy across a heavily pre-treated patient population. What do these results tell you about the drug’s potential as you move into Phase II? 2. Phase II strategy and near-term catalysts Percheron has outlined an adaptive, multi-arm Phase II trial and confirmed manufacturing timelines for clinical supply. How does this design accelerate development, and what milestones should investors watch now? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Percheron Therapeutics (ASX:PER): Phase I success and Phase II pathway for HMBD-002
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5DQzY2RDZFRUQyRDlDQkMw

Percheron Therapeutics (ASX:PER): Phase I success and Phase II pathway for HMBD-002

Teaminvest Private Group (ASX: TIP) is an ASX-listed investment house operating across education and advice, funds management and direct equity ownership in medium-sized businesses. In the half-year to 31 December 2025, TIP delivered strong operating cashflow, continued disciplined investment and materially strengthened its cash position while returning capital to shareholders. CEO Andrew Coleman joins The Stock Network’s Lel Smits to discuss the Company’s performance, capital allocation and opportunities across its three operating divisions. 1. Strong cashflow and capital allocation discipline TIP has just released your half year results where you maintained shareholder returns while investing for growth. What were the highlights of the results for you and how do you decide where to invest capital from this point? 2. Expanding TIP’s Funds Management & Education businesses TIP has stated it's looking to expand its Funds Management and Education businesses - why do you think now is a good time and how are you going to use your research and investor network to turn this into a growth opportunity? 3. Active equity ownership and long-term value creation TIP continues to invest directly in high-quality, cash-generative businesses with strong leadership teams and enduring moats. How does this approach build value creation across your portfolio and how will you build upon it in the year ahead? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Teaminvest Private Group (ASX: TIP): Disciplined investing growth
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43Q0UyODJENjc3NDRCODU0

Teaminvest Private Group (ASX: TIP): Disciplined investing growth

Pengana Capital Group (ASX:PCG) is a diversified funds management group and the group behind the TermPlus investment platform. TermPlus is an online term account provider designed to give Australian investors monthly income generated through diversified access to the global private credit sector – a sector that has traditionally been the domain of large institutions. Built around diversification, floating-rate income, and ease of use, TermPlus reflects the changing realities of income investing for Australian investors. Ahead of Wholesale Investor’s Emergence 2026 Conference, I’m joined by Dean Weinbren, Managing Executive at TermPlus, to discuss how income portfolios are changing, why global private credit has become increasingly relevant for Australian investors, and what investors should be thinking about as they reassess how their money works for them. 1. The shift toward income and stability With market volatility and uncertainty persisting, Australian investors have increasingly favoured income-oriented strategies with more stable return profiles. What do you see as the key drivers behind this shift in investor behaviour? 2. Changing dynamics in traditional income assets Parts of the traditional income universe - including bank hybrids - have contracted or disappeared altogether. To what extent has this structural change accelerated investor demand for alternative income solutions? 3. Understanding global private credit TermPlus delivers monthly income sourced from the global private credit market - an asset class long used by institutions but relatively new for Australian investors at scale. How do you explain what global private credit is, and how it differs from the Australian private credit market, to someone encountering it for the first time? 4. Making private markets accessible Private markets are often perceived as complex and difficult to access. How has TermPlus been structured to simplify access while maintaining institutional-grade investment discipline? 5. Risk, realism and long-term outcomes No asset class is risk-free, and investor education remains critical. How do you frame risk in a balanced and transparent way while setting realistic expectations for investors? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
TermPlus by Pengana Capital Group (ASX:PCG): Investing game plan for private market exposure in 2026
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4yM0YxNkQ4MTExRjg4RUI2

TermPlus by Pengana Capital Group (ASX:PCG): Investing game plan for private market exposure in 2026

After a prolonged reset across private markets, conditions are now turning. Transaction activity is lifting, capital markets are reopening and exit pathways are becoming clearer, setting up a more constructive environment for private equity investors in 2026. Pengana Private Equity Trust (ASX:PE1) gives Australian investors access to global private markets via a single ASX-listed vehicle, providing diversified exposure across private equity, private credit and opportunistic investments. Joining The Stock Network’s Lel Smits, Executive Director Adam Myers discusses what’s changing, why it matters, and how investors can access global private market leaders through Pengana Private Equity Trust. 1. Portfolio positioning for 2026 After a tough few years for private equity, the environment finally feels like it’s shifting. From your seat, what’s actually improving on the ground - deal activity, valuations, exits - and how Pengana Private Equity Trust is positioned to take advantage as conditions turn more favourable in 2026? 2. Private markets and differentiated return drivers One of the biggest shifts you’ve flagged is capital markets reopening. How important is this reopening for private equity returns and sentiment, and how does Pengana Private Equity Trust’s exposure to assets like SpaceX and OpenAI fit into that opportunity set? 3. Accessing private markets through PE1 For investors who may be less familiar with private markets, how do they actually access Pengana Private Equity Trust? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _ None of Pengana Private Equity Trust (“PE1”), Pengana Investment Management Limited (ABN 69 063 081 612, AFSL 219 462) (“Responsible Entity”), Grosvenor Capital Management, L.P., nor any of their related entities guarantees the repayment of capital or any particular rate of return from PE1. Past performance is not a reliable indicator of future performance, the value of investments can go up and down. This document has been prepared by the Responsible Entity and does not take into account a reader’s investment objectives, particular needs or financial situation. It is general information only and should not be considered investment advice and should not be relied on as an investment recommendation. Pengana Investment Management Limited (Pengana) (ABN 69 063 081 612, AFSL 219 462) is the issuer of units in the Pengana Private Equity Trust (ARSN 630 923 643) (the Trust). Before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. An investment in the Trust is subject to investment risk including a possible delay in repayment and loss of income and principal invested.
Pengana Private Equity Trust (ASX: PE1): Accessing the world’s hardest-to-reach growth assets
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4zQTkyMjEwN0U0QkU3RDg5

Pengana Private Equity Trust (ASX: PE1): Accessing the world’s hardest-to-reach growth assets

INOVIQ (ASX:IIQ) is a biotechnology company developing new exosome-based diagnostics and therapeutics aimed at improving how cancer is detected and treated. The company has recently announced positive early-stage results from animal studies showing its CAR-exosome cancer therapy significantly reduced tumour growth, was safe, and improved survival in a breast cancer model. Ahead of Wholesale Investor’s Emergence 2026 Conference, INOVIQ Chief Executive Officer Dr Leearne Hinch joins The Stock Network’s Lel Smits to discuss what these results mean, how the technology works, and the next steps toward human trials. 1. What the latest study showed INOVIQ’s CAR-exosome therapy reduced tumour growth by more than 60% in a triple-negative breast cancer mouse study, with all treated animals surviving and no major safety concerns observed. In simple terms, what did this study show and why is it an important milestone for INOVIQ? 2. Why exosome therapies matter Unlike traditional cell therapies, INOVIQ’s CAR-exosomes are cell-free, designed to precisely target cancer cells while avoiding damage to healthy tissue. Why is this exosome-based approach potentially safer and easier to use than existing autologous T cell therapies? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
INOVIQ (ASX:IIQ): Advancing cancer treatment with next-generation exosome therapy
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5DNzNDRDE1NzhGODQzODI2

INOVIQ (ASX:IIQ): Advancing cancer treatment with next-generation exosome therapy

Prime Financial Group (ASX:PFG) is an integrated advice, capital and asset management group built around connected advice at scale. With around $1.9 billion in funds under management, a 27-year track record and a global footprint, Prime is positioned at the centre of several powerful structural tailwinds reshaping the Australian mid-market. Ahead of Wholesale Investor’s Emergence 2026 Conference, Partner – Sales & Distribution Darren Reed speaks with The Stock Network’s Lel Smits about where growth is coming from next. 1. Structural growth themes Intergenerational wealth transfer, private markets and alternatives, M&A and succession, technology-enabled advice and mid-market expansion are all accelerating. Which of these themes are currently driving the strongest growth for Prime, and how is the Group positioned to capture the opportunity? 2. Private markets and mid-market opportunity Capital is increasingly flowing into private markets, property and alternative assets, while mid-market businesses remain active across M&A and capital raising. How does Prime’s approach translate these trends into scalable earnings growth? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Prime Financial Group (ASX:PFG): How to invest in sports as a booming alternative asset class
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43MzBFRTZDMUM3OTY2RjQ4

Prime Financial Group (ASX:PFG): How to invest in sports as a booming alternative asset class

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy